REGENERON PHARMACEUTICALS, INC. (REGN) FY2026 Q2 Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2026-06-30

Swipe to see the full flow
REGENERON PHARMACEUTICALS, INC. (REGN) FY2026 Q2 Balance SheetBalance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.Current liabilities$5.53 BLiabilities$10.02 BCurrent assets$18.45 BNon-current liabilities$4.49 BAssets$41.73 BEquity$31.71 BGross equity(calculated)$52.32 BNon-current assets$23.28 BHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSAccounts receivable, netMarketable securitiesInventoriesCash and cash equivalentsPrepaid expenses and other current assetsMarketable securitiesProperty, plant, and equipment, netDeferred tax assetsOther noncurrent assetsIntangible assets, netAccrued expenses and other current liabilitiesAccounts payableFinance lease liabilitiesDeferred revenueOther noncurrent liabilitiesLong-term debtDeferred revenueRetained earningsAdditional paid-in capitalCommon stock - Common StockCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Treasury Stock, at cost; 36.4 shares in 2026 and 33.7 shares in 2025Accumulated other comprehensive (loss) incomeAccrued expenses and other current liabilitiesAccrued expenses and other current liabilities$2.97 BCurrent liabilitiesCurrent liabilities$5.53 BAccounts payableAccounts payable$1.16 BLiabilitiesLiabilities$10.02 BFinance lease liabilitiesFinance lease liabilities$720.00 MCurrent assetsCurrent assets$18.45 BDeferred revenueDeferred revenue$684.80 MAccounts receivable, netAccounts receivable, net$6.57 BNon-current liabilitiesNon-current liabilities$4.49 BOther noncurrent liabilitiesOther noncurrent liabilities$2.28 BAssetsAssets$41.73 BMarketable securitiesMarketable securities$5.54 BEquityEquity$31.71 BLong-term debtLong-term debt$1.99 BInventoriesInventories$3.08 BDeferred revenueDeferred revenue$220.40 MGross equity (calculated)Gross equity(calculated)$52.32 BCash and cash equivalentsCash and cash equivalents$2.46 BPrepaid expenses and other current assetsPrepaid expenses and other current assets$801.70 MNon-current assetsNon-current assets$23.28 BMarketable securitiesMarketable securities$9.83 BRetained earningsRetained earnings$37.62 BProperty, plant, and equipment, netProperty, plant, and equipment, net$5.46 BDeferred tax assetsDeferred tax assets$4.38 BOther noncurrent assetsOther noncurrent assets$2.31 BIntangible assets, netIntangible assets, net$1.31 BAdditional paid-in capitalAdditional paid-in capital$14.70 BCommon stock - Common StockCommon stock - Common Stock$100.00 KTreasury Stock, at cost; 36.4 shares in 2026 and 33.7 shares in 2025Treasury Stock−$20.57 BAccumulated other comprehensive (loss) incomeAccumulated other comprehensive (loss) income−$35.80 M
Chart details

REGENERON PHARMACEUTICALS, INC. (REGN) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets
41,730,600,000 US dollars
Current assets
18,446,000,000 US dollars
Non-current assets
23,284,600,000 US dollars
Liabilities
10,019,200,000 US dollars
Current liabilities
5,530,600,000 US dollars
Non-current liabilities
4,488,600,000 US dollars
Equity
31,711,400,000 US dollars
Accounts receivable, net
6,565,400,000 US dollars
Marketable securities
5,538,800,000 US dollars
Inventories
3,084,300,000 US dollars
Cash and cash equivalents
2,455,800,000 US dollars
Prepaid expenses and other current assets
801,700,000 US dollars
Marketable securities
9,828,300,000 US dollars
Property, plant, and equipment, net
5,458,900,000 US dollars
Deferred tax assets
4,381,400,000 US dollars
Other noncurrent assets
2,306,200,000 US dollars
Intangible assets, net
1,309,800,000 US dollars
Accrued expenses and other current liabilities
2,966,500,000 US dollars
Accounts payable
1,159,300,000 US dollars
Finance lease liabilities
720,000,000 US dollars
Deferred revenue
684,800,000 US dollars
Other noncurrent liabilities
2,281,600,000 US dollars
Long-term debt
1,986,600,000 US dollars
Deferred revenue
220,400,000 US dollars
Finance lease liabilities
0 US dollars
Retained earnings
37,621,400,000 US dollars
Additional paid-in capital
14,700,600,000 US dollars
Common stock - Common Stock
100,000 US dollars
Common stock - Class A Stock
0 US dollars
Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none
0 US dollars
Treasury Stock, at cost; 36.4 shares in 2026 and 33.7 shares in 2025
negative 20,574,900,000 US dollars
Accumulated other comprehensive (loss) income
negative 35,800,000 US dollars
Gross equity (calculated)
52,322,100,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
REGENERON PHARMACEUTICALS, INC. (REGN) FY2026 Q2 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!